

XBiotech Inc.
Form 8-K/A
December 06, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2016

XBIOTECH INC.
(Exact name of Registrant as specified in its charter)

**British
Columbia,
Canada**
(State of
Incorporation)

001-37347
(Commission File Number)

N/A

(I.R.S. Employer Identification No.)

8201 E Riverside Dr. Bldg 4, Ste 100

78744

Austin, Texas

(Zip Code)

(Address of principal executive offices)

(512) 386-2900

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

EXPLANATORY NOTE

This Current Report on Form 8-K/A is being filed by XBiotech Inc. (the “Company”) solely to more accurately state information contained under Item 8.01 of the Company’s Current Report on Form 8-K with the Securities and Exchange Commission on December 5, 2016 (the “Original Report”). Specifically, the Original Report reflected the number of Patents and Patents Pending held by the Company as 120+. The more precise number of Patents and Patents Pending is 180. We have also updated the biographical information for one of our Directors.

In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, the corrected presentation as Exhibit 99.1 of the Original Report, is attached hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 XBiotech Presentation Slides

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 5, 2016 XBIOTECH INC.

By: /s/ John Simard
John Simard
Chief Executive Officer and President

EXHIBIT INDEX

Exhibit Number Description

99.1	XBiotech Presentation Slides
------	------------------------------------